Free Trial

Sensus Healthcare (NASDAQ:SRTS) Price Target Cut to $6.00 by Analysts at Lake Street Capital

Sensus Healthcare logo with Medical background

Key Points

  • Lake Street Capital has lowered its price target for Sensus Healthcare (NASDAQ:SRTS) from $13.00 to $6.00, while maintaining a "buy" rating, indicating a potential upside of 73.41% from the current price.
  • Other research firms have also recently revised their outlook, with Wall Street Zen downgrading the stock to a "sell" rating, and Maxim Group adjusting their target price to $10.00.
  • Sensus Healthcare reported earnings results that missed analysts' expectations, with a loss of ($0.06) per share and revenue of $7.32 million, compared to the anticipated $9.30 million.
  • Looking to export and analyze Sensus Healthcare data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Sensus Healthcare (NASDAQ:SRTS - Free Report) had its price target lowered by Lake Street Capital from $13.00 to $6.00 in a report issued on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

SRTS has been the topic of a number of other reports. Maxim Group cut their price target on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Wall Street Zen lowered Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd.

Get Our Latest Analysis on Sensus Healthcare

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock traded down $0.08 during trading hours on Friday, hitting $3.11. The company's stock had a trading volume of 245,204 shares, compared to its average volume of 191,778. Sensus Healthcare has a 12 month low of $3.03 and a 12 month high of $9.33. The stock has a 50 day moving average of $4.81 and a 200 day moving average of $4.96. The company has a market capitalization of $51.05 million, a PE ratio of -51.35 and a beta of 1.34.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $0.01 by ($0.07). The firm had revenue of $7.32 million during the quarter, compared to the consensus estimate of $9.30 million. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.56%. Equities analysts expect that Sensus Healthcare will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SRTS. Larson Financial Group LLC acquired a new position in Sensus Healthcare during the first quarter valued at approximately $26,000. JPMorgan Chase & Co. acquired a new position in Sensus Healthcare during the fourth quarter valued at approximately $27,000. Barclays PLC acquired a new position in Sensus Healthcare during the fourth quarter valued at approximately $35,000. BNP Paribas Financial Markets acquired a new position in Sensus Healthcare during the fourth quarter valued at approximately $47,000. Finally, Vise Technologies Inc. acquired a new position in Sensus Healthcare during the second quarter valued at approximately $52,000. 25.30% of the stock is owned by institutional investors and hedge funds.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Read More

Should You Invest $1,000 in Sensus Healthcare Right Now?

Before you consider Sensus Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.

While Sensus Healthcare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines